HPPK must transfer a pyrophosphate moiety from ATP to 6-hydroxymethyl-7,8-dihydropterin (DHP) to create folate cofactors.⁶⁵ Folate synthesis begins with HP. HP is needed for several carbon-atom transfer processes.⁶⁶ Folic acid synthesizes amino acids, purines, and pyrimidines for cell metabolism, growth, and function.⁶⁷ Prokaryotic and lower eukaryotic microbes manufacture folate using HPPK, but mammals and other higher eukaryotic organisms source it from their diet.⁶⁵ DHPPP is formed when the tiny 18 Kda protein HPPK aids the magnesium-dependent conversion of pyrophosphate from ATP into DHP.⁶⁸ Two necessary Mg2+ ions coordinate the triphosphate moiety of ATP, and a conserved gap between enzyme loop portions holds the adenosine ring in place. DHP places the pterin ring between two well-preserved aromatic amino acid residues in a nearby molecular pocket.⁶⁹ A detailed investigation of ligand-free HPPK compared to its tripartite complex with DHP and ATP found that loops 1–3 are HPPK's functional location.⁷⁰ Catalytic residues R82 and R92 now occupy the optimum Mg-ATP-binding site due to the conformational shift.^71,72 HPPK-targeted drugs are important because DHPS mutations reduce the efficacy of sulfa-containing antibiotics.⁹ The lack of an HPPK substrate and catalytic process expertise complicates active site drug design.⁷³

Virtual screening and X-ray crystallography revealed a W89-L45 cryptic pocket near HPPK's pterin-binding site. Computer simulations of HPPK–pharmacological candidate interactions showed conformational changes.⁷⁴ Virtual screening predicts that the protein will interact with several small ligands, revealing a cryptic pocket through conformational changes. X-ray crystallography validated and captured high-resolution static HPPK structures down to the atomic level, revealing the cryptic pocket structure. Many HPPK inhibitors were found via high-throughput screening in 2014. One of these compounds modified loops 2 and 3 with an aryl-substituted 8-thiaoguanine scaffold, displacing L45, W89, and R92. Thus, an extra pocket was generated next to the pterin-binding pocket (Table 1; Figure 4A, B).⁹ X-ray crystallography showed that 1 and 2 interact with HPPK's active site and cryptic pockets. The pterin pocket squeezed free 8-thioguanine between Y53 and F123, which created precise hydrogen bonds with residues T42 and N55's side chain moieties due to its nitrogen and oxygen atoms. The nucleotide's α- and β-phosphate moieties are coupled to R82 and R92 in the cryptic pocket via salt bridges created with D95 via the 8-thio substituent. 1 and 2 bonded to an HPPK, AMPCPP, and DHP ternary complex. The carbonyl group in the linker between 8-thioguanine and phenyl rings may be responsible for the higher HPPK inhibition in structure 1 (Kd = 9.7 μM and IC₅₀ = 139 μM) compared to structure 2 (Kd = 29 μM and IC50 = 254 μM).⁹ The phenyl ring replacements 3–8 resulted in increased inhibitory effectiveness (IC₅₀ = 44–88 μM), likely due to the carbonyl moiety in 1. Smaller replacements on 1, such as 3, 4, 5, 7, and 8, were favored over larger ones, such as 6. The optimized ternary complexes showed that phenyl groups 3 and 7 could access the protein's cryptic pocket within 1 Å, unlike group 1 (Figure 4C). These stacking interactions strengthened the connection between R121's guanidine groups and 1's flat carbonyl. SARs set a standard for structural change based on these molecules' pharmacological and biophysical properties.⁹ Using the model (Figure 4D),¹⁶ we determined the binding conformations of 8MG and its S-benzylated derivatives, which had electronegative and electropositive moieties in the aromatic rings at ortho, meta, and para positions in the cryptic pocket. X-ray crystallographic studies show that the cryptic pocket binding behavior is identical to that of S-benzylated 8MG derivatives, including those with a p-cyanobenzyl-substituent (1.96 Å). The structure connects the guanine moiety of 10 to the protein via six hydrogen bonds. The core heterocyclic motif stacks π-electronically with the aromatic components of F54 and F123. The benzyl group was found in the small gap produced by the thiol extension between loops 2 and 3 residues 47–51 and 84–91. The sulfur atom in 10 is now about 1 Å further away from the pocket, allowing the binding site to be optimally occupied. The aliphatic moieties amino acid residues P45, Y48, Q51, F54, and W89 exhibited hydrophobic interactions with the benzyl ring, while residues N11, Q51, G90, and P91 were electrostatically bound to the nitrile moiety. The inhibitory effect against EcHPPK was intensified by substituents, showing that compounds with m-methyl (11, Kd = 0.965 μM), p-fluoro (12, Kd = 1.4 μM), and p-methoxy (13, Kd = 0.95 μM) substituents had significantly higher binding affinity. The p-cyano (10) and p-fluoro (9) derivatives showed improved binding affinities to SaHPPK, with Kd values of 0.30 μM and 0.33 μM, respectively. Thus, lead compounds modified with halogen substituents showed greater promise as broad-spectrum HPPK inhibitors. The flexibility of the functional domain loop and critical residues makes the creation of highly potent HPPK inhibitors difficult. The cryptic binding sites around the main active sites may solve this problem. Since the SARs for both active site inhibitors and those binding in the cryptic pocket of HPPK have been established, this information can be utilized to change inhibitor structures and construct very effective antibiotics for this region. Further investigation is also required to determine how to crystallize the protein using the particular framework found in the cryptic pocket. An essential component in optimizing potential inhibitors, such atomic resolution would yield an incontestable binding model between inhibitors and cryptic pockets.

Bacteria metabolize p-aminobenzoic acid (pABA) and 6-hydroxy methyl-7,8-dihydropterin pyrophosphate (DHPPP) to dihydropteroate, an essential folic acid intermediary.^75,76 Dihydropteroate is generated when PABA's amino group displaces PPi from DHPPP.⁷⁷ Dihydropteroate produces nucleic acids during cell growth.⁷⁵ The complex's Fourier electron density map⁷⁸ reveals a conserved DHPPP-binding site in DHPS's eight-stranded α/β barrel structure, resembling a bent cylinder. DHPPP and pABA bind sequentially.⁷⁹ The C-terminal end of the β-strands has a deep gap, where DHPPP removes eight water molecules from the unliganded protein. In reference,⁸⁰ the dihydropterin moiety replaces others, while the γ-phosphate of DHPPP replaces one water molecule. Early DHPS antibiotics were sulfonamides.⁸¹ Sulfonamide resistance increases 24 times in bacteria with DHPS gene mutations S382C, A383G, and A437G.⁸² DHPS's amino acid sequence has changed over the past 70 years, making sulfathiazole and sulfadiazine ineffective.⁸³ A study detected sulfa-resistant Plasmodium falciparum in 96% of subjects.⁸⁴ DHPS's retained pterin-binding pocket has been exploited to develop new drugs.¹² This pocket favors pterin substrates and analogues, producing low-solubility pterin-like compounds.⁸⁵ To produce sulfa-resistant drugs, new DHPS regions must be found. NMR and crystallographic investigations indicated a cryptic pocket at the DHPS interface for residues E260, L235, E236, and M264 (Figure 5A). Table 1 shows that DHPS inhibitors targeting cryptic pockets have pterin-like structures. Anthracis DHPS segments were screened with WaterLOGSY NMR and the 1100 chemical Maybridge Ro3 library. Ten of these compounds (14–23) target only the cryptic pocket.¹² Compounds 14–23 considerably reduced DHPS from Bacillus anthracis (86%), Yersinia pestis (61%), and Staphylococcus aureus (46%), while compounds 15–23 had very mild inhibitory effects at 250 μM. Imine 24, made from 14, completely inhibited DHP enzymes in three bacteria at 250 μM (Figure 5B). The IC₅₀ values for this chemical were 50, 17, and 31 μM. Loop 7's X-ray cocrystal structure showed 24 additional residues linked to V231, E232, E233, R234, and L235. More interaction between loops 1 and 7 increases the possibility of loop 1 remaining in the active site and not releasing the product. Due to its weak physicochemical properties, it has little antibacterial activity, but it can be exploited as a lead molecule to develop stronger antimicrobials. Additional antifolate medicines and stronger cryptic pocket treatments could decrease resistance. X-ray co-crystal structural data of 11 derivatives can be used to increase drug-binding affinity to the cryptic pocket or inhibit DHPS's catalytic activity by interacting with pterin, PABA, and cryptic binding sites to reduce antibiotic resistance.

Stage 4 lipid The enzyme LpxH removes the pyrophosphate linkage from UDP-2,3-diacylglucosamine (UDP-DAGn) to produce lipid X.^86,90 This step initiates membrane-bound lipid A production. Gram-negative bacteria survive on lipid A, a hydrophobic lipopolysaccharide.⁸⁸ LpxH is a prospective therapy target because 70% of gram-negative bacteria use it as an enzyme.^10,89,90 Research indicates that LpxH contains just two central β-sheets, unlike PP-1, which has three in its core catalytic domain.⁸⁷ According to,⁸⁷ LpxH's two β-sheets form a separate structure that connects to β-sheet 2, forming two parallel β-chains. The “pitfall trap” cover plate in lipid X resembles the α2′ junction between α1′/α3′ helices.⁹¹ Mn2+ ions' high electron densities in LpxH's functional motif, the core domain and insertion lid, affect enzyme performance.⁹² D42 bridges the manganese clusters, binding Mn1, while D9, D11, N80, H195, and H196 bind Mn2.⁹³ By replacing these residues with alanine, LpxH's enzymatic activity decreases by 5,000 to 200,000.⁸⁷ No LpxH-active site conformation-specific drugs have been designed or tested.⁹⁴ Mutagenic experiments showed LpxH mutations G48D, L84R, F141L, and R149H to be protective against sulfonyl piperazine scaffold chemicals.¹⁷ Gram-negative bacteria can avoid multidrug resistance with LpxH inhibitors. Locating LpxH's cryptic pockets may allow drug-resistant structural molecules.

Nuclear magnetic resonance (NMR) analysis of LpxH found an L-shaped hydrophobic chamber as a cryptic binding site and explained how it changed conformational and structural states (Figure 6A; Table 1). In a 384-well configuration, 1.2 million compounds were screened for enzyme activity at 50 μM doses.¹⁷ AZ1 (25), a chemical compound with indoline and piperazine groups, inhibited E. coli efflux mutants at 0.25 μg/mL but not wild-type E. coli at concentrations above 64 μg/mL. Since 25 inhibited G48D, L84R, F141L, and R149H mutants 512-fold less than LpxH, it appeared to interact closely with them. 25 alters Gram-negative cell outer membrane biogenesis, making them antibiotic-resistant. 25 is hydrophobic and strongly binds protein in human plasma; hence, mammals should not get it.¹⁷ Analogues of phenol, benzoic acid, and phenyl improved 25's physical characteristics. All derivatives (JH-LPH-4 to JH-LPH-26) demonstrated a 4- to 28-fold decrease in inhibitory efficacy compared to 25 (IC₅₀ values: 0.14 μM for E. coli and 0.36 μM for Klebsiella pneumoniae). SARs showed a one AZ1 pharmacophore with one hydrogen-bond acceptor (carbonyl oxygen of the N-acetyl group on the indoline ring), two hydrophobic groups (indoline and piperazine rings), and two aromatic rings (benzene rings) for sulfonyl piperazine-based LpxH inhibitors.¹⁰⁰ 25 interacted with LpxH's L-shaped cavity, placing its indoline ring near the catalytic site (Figure 6B).¹⁰ In K. pneumoniae LpxH, the indoline group formed complexes with lipophilic amino acids F82, L83, Y125, F128, I137, F141, I152, A153, and M156 by van der Waals contacts and cation–π stacking with R80. The acetyl group of 25 and LpxH residue N79 produced hydrogen connections, as did the sulfonamide moiety with residues R157 and W46. The LpxH-bound conformation of 25 was used to create two derivatives of 25: JH-LPH-33 (26) and JH-LPH-28 (28). These compounds were changed by adding chloro or fluoro derivative residues to the met a-configuration of the trifluoromethyl phenyl moiety. Chloro-substituted 26 showed stronger antibacterial activity, with IC₅₀ values of 0.026 μM for K. pneumoniae and 0.046 μM for E. coil (Figure 6C). By contrast, fluoro-substituted 28 yielded IC₅₀ values of 0.11 μM for K. pneumoniae and 0.083 μM for E. coli. With a halogenated group in the hydrophobic cavity, 26's inhibitory activity is 1.7 times stronger and 28's inhibitory activity is 13.8 times stronger. In JH-LPH-41 (27), a long acyl chain derivative of 26, poorer antibiotic action against K. pneumoniae LpxH (MIC = 32 μg/mL) was due to poor membrane penetration (Figure 6D).⁹¹ SAR study showed a positive connection between chemical potency and functional moieties at the meta-position of the CF3-substituted distal aromatic ring. This site was most effective when H, F, CH3, and Cl were replaced in order to increase potency. New LpxH inhibitors could enable MDR research. Three factors prevent LpxH from using a cryptic pocket to reduce resistance: (1) the lack of a completely defined antibacterial activity profile for these inhibitors; (2) the need to modify their structural alterations to increase LpxH-binding affinity; and (3) the necessity to examine their effectiveness and selectivity for multidrug-resistant bacteria.

Essential for bacterial cell division, a filamentous GTPase known as FtsZ forms a dynamic Z-ring within the cell.⁹⁶ Bacterial viability and dynamics are impacted when FtsZ assembly is disrupted.⁹⁷ The key cell division protein in the majority of bacteria is FtsZ, which creates a dynamic Z ring close to the split site. During cell division, GTP regulates the reassembly of the cell wall and the contraction of the filaments.⁹⁸ Inherent polymerization properties of FtsZ, including GTPase activity and lateral connections, govern its dynamics. These factors impact cellular elongation, division, and the recruitment and distribution of cell wall synthases.⁹⁹ A central helix (H7) is located in the N-terminal domain of FtsZ, which is connected to a C-terminal nucleotide-binding domain; protofilaments are formed by the C-terminal domain.^100,101 The GTPase-active site is located between the monomers that make up the FtsZ subunits.¹⁰⁰ A particular T7 ring and the GTP-binding site combine to create the active site.¹⁰¹ G196S and G193D are the most prevalent FtsZ mutations that cause resistance to methicillin and TXA707, respectively.¹⁰² The poor activity and absorption of new antibiotics targeting the thermally sensitive protein Z caused severe harm to the host flora.⁹⁶ Because of this, novel compounds that decrease medication resistance need to be identified and developed. The MD simulation-derived bending of helix H7 in FtsZ was confirmed by X-ray crystallography, which revealed two hidden pockets: BP1 (M49, S50, and N25) and BP2 (E185, N189, E302, R304, and T306) (Figure 7A; Table 1).¹⁰³ The FtsZ function is inhibited by derivatives of coumarin (29 chemicals) and 4-hydroxycoumarin (30 compounds), with IC₅₀ values of 200 μM (Figure 7B).¹³ There is minimal affinity between the nucleotide-bound and 4-hydroxy analogue 30 forms of FtsZ. In addition, it establishes long-lasting links between BP1 and BP2. Extending electron density over the ligand, 30 oC entirely fills the pocket in BP1. Residues L47, M49, and D57 in the hydrophobic area of the binding cavity establish hydrophobic interactions with the benzyl group. The nitrogen atoms of K55 and S50's backbone nitrogen groups are joined by two hydrogen bonds in 4-hydroxycoumarin through carbonyl oxygens. In BP2, 30 is surrounded by G185, N189, Q192 (helix H7), I225 (strand β7), A262 (strand β7), E302, and R304 (strand β10). Figure 7B shows that, similar to BP1, the benzyl group forms hydrophobic interactions with E185, S227, G302, and R304, and that the 4-hydroxy group forms hydrogen bonds. Natural coumarin compounds binding to cryptic pockets decrease FtsZ polymerization and GTPase functions in 3D-QSAR screening, establishing a model for high-efficiency compound screening.¹³ Therefore, delay of drug resistance can be achieved through compound creation with two cryptic pockets.

The cryptic binding pockets make it difficult to find drugs that target FtsZ to reduce its methicillin and TXA707 resistance. (1) Lack of structural data has hampered structure-based drug creation of a high-efficacy inhibitor. The binding conformation between FtsZ and compounds at the atomic level can guide compound structure modification, so drug design should focus on the two cryptic pockets and the active site simultaneously to delay drug resistance and increase FtsZ inhibitor selectivity.

In addition to chloroplasts, the cytosol and glyoxysomes include perox isomes and MDH.¹⁰⁴ Functioning homeostasis requires the rapid conversion of malate into oxaloacetate, which requires NADH, and modification of the cytoplasmic NAD + /NADH ratio.¹⁰⁵ MDH controls the citric acid cycle, gluconeogenesis, metabolic stress, amino acid biosynthesis, oxidation/reduction equilibrium, and pathogens.¹⁰⁴ The dimer end of MDHs has a substrate-binding pocket, while the beginning has catalytic amino acid residues and a NAD-binding motif.¹⁰⁶ Stable MDH dimers have two functional domains. NAD+ or NADP+ catalyzes the irreversible conversion of malic acid into oxaloacetic acid in an MDH cleft.¹⁰⁷ MDH's active site binds the substrate and coenzyme's nicotinamide ring to produce a ternary complex. A protein's structure is altered by an external loop around the active site, catalyzing this vital activity.¹⁰⁷ The ABCB1 transporter may be triggered by MDH overexpression, releasing vinblastine, tariquidar, zosuquidar, colchicine, verapamil, and doxorubicin. This mechanism may boost ATP and produce resistance-associated proteins.¹⁴ MDH increases cancer cell survival and prevents apoptosis by activating JNK. Previous research shows that prostate and uterine cancer cells can become docetaxel- and doxorubicin-resistant.^14,108 Clinical approval of MDH inhibitors is pending due to the lack of bacterial specificity in other active site medicines.¹⁰⁹ Discovery of cryptic areas increases the likelihood of finding MDH inhibitors that safely treat mycobacteria, S. aureus, E. coli, and other bacteria. High-throughput screening and X-ray scattering found MDH subsites 2 (G175-L177), 3 (Q211-M216), and 1 (L250, A272, K273, V282, and F284). Seven chemicals inhibited WT and V190W MDH in 1500 Maybridge library fragments tested by subsite 1 STD NMR. Only 4DT (31)^14,109 shows aromatic high-intensity peaks at 6 and 8 mg/L. Compound 31, with drug-like characteristics, inhibited MDH with a Kd of 99 μM and destabilized it with a △Tm of -2.00 ± 0.17 ◦C in MST tests. When we reached 31, the oligomeric interface's A and C chains were almost filled. It was 60% for chain A and 40% for chain C. V161, M200, F195, and F284 are side chain residues, and 31's sulfur atom has pocket van der Waals interactions. As shown in Figure 8A, the meta fluorine moiety engages the V169, V187, and N188 side chains. MDH's tetrameric structure remained intact after binding to 31; however, residues L250, V282, and K273 altered significantly in the A/D and B/C chains. Isopropyl derivatives induced steric effects, chlorine and bromine had high atomic radii, and nitrile had tri-fluoromethyl groups and electron-withdrawing effects. Fourb (35) and 7a (38), the two most potent 2 mM inhibitors, inhibited MDH activity by 80% and 77%, respectively, after 5a (36, 48%) and 5b (37, 47%). Compounds 1b (32, 40%), 2b (33, 35%), 4a (34, 35%), and 9a (39, 49%) inhibited MDH, unlike compound 31, which had low SO42 levels. The metaposition's trifluoromethyl group drastically reduced MDH's thermal stability, demonstrating that large functional groups can abolish it. 4DT compounds inhibited MDH non-competitively and lowered malate-binding affinity with different substrate concentrations.¹¹⁰ High-throughput screening demonstrated that ZINC database chemicals CHLM, ACEE, ACTO, ETHR, ETOH, and CYPO strongly affected subsite 2. The majority of BIPH, ACET, CHLM, ACTO, DPME, and BENZ connected to subsite 3.¹¹¹ Since the host cytoplasm lacks similar cryptic sites, reasonably designed MDH agonists can target these sites (Table 1). The following issues need to be further studied, but lead drugs that target MDH's cryptic pockets have been identified: Most drugs work better at suppressing oligomeric and tetrameric MDH, which affects pathogen metabolic processes such as the citric acid cycle, gluconeogenesis, amino acid synthesis, etc. Low water solubility decreases bioavailability and complicates IC₅₀ calculations for 4DT drugs. The inhibitory and selective actions of these chemicals must be understood to improve membrane permeability through structural alterations targeting molecules with higher affinity and modifying their physicochemical properties.

The four β-lactamase groups (A, B, C, and D) are mostly characterized by amino acid sequences in the BLA domain.¹¹⁸ Some antibiotics depend on hydrolase β-lactamase. The serine moiety in the catalytic domain classifies β-lactamases as class A, C, or D. Due to zinc ions in their catalytic site, metallo-β-lactamases (MBLs) are classified as class B.¹¹³ All pharmacologically licensed β-lactam antibiotics have a basic tetrameric azetidinone ring.¹¹⁴ Gram-negative bacteria can produce β-lactamases, leading to resistance to β-lactam antibiotics. Carbapenem, cephalosporin, penicillin, and mono-bactam are less effective because these enzymes break the core four-membered azetidinone.⁴ Gram-negative bacteria create β-lactamases in the periplasmic compartment, while Gram-positive bacteria create them in the cytoplasmic membrane. Different sites cause the two types of bacteria to break down β-lactam drugs differently.¹¹⁵ Combining β-lactams with specific β-lactamase inhibitors can improve their effectiveness against β-lactamases.^116,117 In healthcare settings, azobactam, sulbactam, and clavulunate were the first β-lactamase inhibitors used.¹¹⁸ The medications mostly targeted Class A β-lactamases, while Class D had varied inhibitory effects and Class B had no impact. In the past decade, β-lactam/β-lactamase inhibitors such ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/relebactam have been used to treat drug-resistant infections.^125–127 Porin reduction or carbapenemase (class B and D) overexpression may make bacteria resistant to these drugs.¹²² No class B β-lactam inhibitor medicines are currently approved for clinical studies. This limits hospital treatments for severe multidrug-resistant diseases.¹²³ Development of effective β-lactamase inhibitors, particularly for classes B and D, is crucial. Table 1 shows that TEM-1 and CTX-M-9 β-lactamases hydrolyze cefotaxime, and cryptic pockets can target them. Combined use of computational (MD simulation) and experimental (NMR) methods revealed the cryptic pockets of TEM-1 β-lactamase.^124,125 In Figure 9A, they are located between the Ω-loop pocket, helix H11 (271–289), and helix H10 (218–230). In 2004, a virtual screening found two compounds from the Maybridge library as candidate ligands for the TEM-1 β-lactamase cryptic pocket between helices 11 and 12. 3-(4-phenyl amino-phenylamino)-2-(1H-tetrazol-5-yl)-acrylonitrile and N,N-bis(4-chlorobenzyl) are compounds 1 and 2.1,H-indolyl tetraazol-5-amine. Residues 274–285 were shifted 1–3 Å from their apo locations, while residues 218–224 had α-carbon atoms displaced 3–7 Å, disrupting the secondary structure (Figure 9B).¹²⁶ 41 and 42 largely interacted with residues L221, L250, I279, and L286 (pocket walls) and I246, V261, and I263 (pocket foundation). The activity center was 16 Å from the contact point. Because these compounds change shape, substitution of R244 reduces catalytic activity. In typical β-lactam substrates, the residue interacts with the C3′ carboxylate group. Both drugs suppressed wild-type TEM-1 β-lactamase and two mutants: M182T (480 μM and 460 μM) and G238A (590 μM and 590 μM). The NCI/DTP Open Chemical Repository improved compounds targeting the cryptic pocket between helices H10 and H11 by virtual screening. The activators and inhibitors were NSC350086 (43), NSC333009 (44), and NSC341597 (45).¹²⁷ All four 43 isomers, with an EC₅₀ value of 162 μM, significantly increase nitrocefin catalytic efficiency (kcat/Km) by 52%. In Figure 9C, compound 44 increases kcat/Km by 52% at 162 μM EC₅₀, while compound 45 lowers it by 59% at 57 μM. TEM-1 β-lactamase catalytic activity was reduced by these three medications. 0.01% Triton-X inhibited 44 and 45 enzymes equally, suggesting that aggregation drives its non-selective mechanism. However, 43 did not work without Triton-X, validating a theory concerning its interaction with TEM and showing that its inclusion is necessary for 43's process. Mutation research demonstrates that the three chemical entities' alkyl chain portions form van der Waals bonds with L220, T265, and R 244. TEM-1 cryptic pockets require energy to open; thus, CYMAL-6 was added to aid detection. The chemical is the single TEM-1 inhibitor, with a Ki value of 40.05 μM and efficacy with 0.5 mM SDS.¹²⁸ Two CYMAL-6 and TEM-1 crystal structures exist. CYMAL-6's complex H bonds with H11C-terminal E280 and H10C-terminal V create similar complexes. Its cyclohexyl moiety and lengthy aliphatic amino acid sequence fit well in a hydrophobic pocket formed by A280, G283, I221, A268, and V261. primary structures (2A3U, 5EEB, 4ZAM, 4R3B, and 4MBF) had the cyclohexyl moiety from CYMAL-6 in their grooves, while secondary entities (1PZP, 1PZO) migrated away from H10 in the hydrophobic core. Next, half a million pounds from the ZINC database were high-throughput-screened. The highest Glide scores were reported in anisole (ZINC12026660 (46), ZINC19908919 (47), ZINC40961289 (48), and N-benzylacetamide derivatives). N-benzylacetamide and its anisole moieties were strategically positioned in the cyclohexyl segment of CYMAL-6, and the aromatic rings interact with R244 via pi–cation interactions. By targeting the cryptic pocket, natural humic substances may inhibit TEM-1. Only the coal humic acid (CHM) ethanol-soluble fraction from SHA, CHM, CHI, PHA, and CHP lowered TEM-1 catalysis by 42%. CHM may inhibit TEM-1 due to non-specific interaction between CHM compounds, the protein surface, and low-molecular-weight CHM constituents in the cryptic pocket, which affects the active site structure.¹²⁹ The only conserved Ω-loop cryptic site is found in TEM and CTX-M-9 β-lactamases.¹²⁵ Mutations (E240D/R241P) in the Ω-loop cryptic pocket indicate that pocket opening can increase benzylpenicillin activity, suggesting a potential therapeutic target. Using compounds that target cryptic pockets can minimize antibiotic resistance by reducing β-lactamase hydrolysis. Research on chemicals that target cryptic crevices in β-lactamases is crucial for modifying lead compounds' structures. Limitations exist in the use of cryptic pockets to tackle β-lactamase-induced antibiotic resistance: (1) Improving TEM-1 β-lactamase cryptic pocket inhibitor binding and efficacy; (2) testing Ω-loop drug design for efficacy; and (3) evaluating synergistic effects of active and cryptic pocket inhibitors. This method can combat antibiotic resistance and identify inhibitors in class B, C, and D β-lactamases. This can hinder the degradation of β-lactam medicines by various β-lactamases.

DsbA controls protein folding, efficiency, and secreted state integrity.¹³⁰ Periplasmic synthesis affects extracellular proteins and multimeric cell surface structures.¹³¹ Failure to synthesize enough DsbA causes protein misfolding and emergence of harmless microorganisms.¹³⁰ DsbA has known helical sections and a TRX domain.¹³² The structure of the TRX domain resembles disulfide oxidoreductases, featuring four β-strands and two α-helices (β4β5β6 and β2α1β3 motifs). DsbA's active site contains the TRX domain's conserved CXXC motif (C30-F31-H32-C33).¹³³ The low-pKa reduced thioalte ion C30 is stabilized by hydrogen bonding with carbon atoms C33 (thiol) and H32 (backbone amide nitrogens).^140,141 A TRX domain cis-proline loop aids substrate binding and thioredoxin fold protein redox modification.^136,137 The broad hydrophobic helical domain above the active site interacts with substrates to stabilize and select substrate binding.¹³⁸ “Target bypassing,” which favors pathogenic virulence over viability, reduces antibiotic resistance.¹³⁹ Antibiotic resistance can be reduced by targeting virulence modulator DsbA.¹⁴⁰ However, existing DsbA inhibitors require a cysteine mutation to interact with the active site.^141,142 Novel DsbA pockets may enable the formation of non-covalent inhibitors. X-ray crystallography and NMR investigations showed that reorienting Y110 in DsbA resulting in the formation of the cryptic pocket (Y110, L112). In 2021, the Monash Institute for Pharmaceutical Science (MIPS) fragment libraries were used for ligand-detected saturation-transfer difference (STD) NMR high-throughput screening of 1,130 fragments for DsbA's cryptic pocket (Figure 10A; Table 1).¹⁵ Bromophenoxy propanamide (fragment 1 (51)) and 4-methoxy-N-phenylbenzenesulfonamide (fragment 2 (52)) were chosen because they preferentially bind with BpsDsbA's oxidized catalytic region (Figure 10B). The crystal structures of the symmetry-related protein showed V12, A13, and K15, while 51 hydrophobically interacted with the secondary moieties of Y110, W40, F77, and L112 in the original protein. The aromatic rings of 51 and Y110 had π-stacking interactions within 10 Å of the redox active-site residue C43. The fragments likely inhibited DsbA (Kd > 2 mM) due to their tiny surface areas and partial pocket occupancy. A fluorescently tagged synthetic peptide with cysteines or fragments reduced the BpsDsbA–BpsDsbB redox cycle at 20 mM in a peptide-oxidation experiment. These results showed that peptides 51 and 52 lacked the binding affinity to inhibit or compete with BpsDsbA. However, these compounds may improve DsbA-binding molecules. DsbA's cryptic pocket may lead to the formation of effective inhibitors via structural derivations and optimization of 51 and 52. In vivo testing to determine if the inhibitor kills DsbA bacteria is also needed. The close proximity of the cryptic and active sites suggests that drugs binding to both pockets can synergistically suppress pathogens.